Etanercept-Induced Thrombocytopenia In A Patient With Ankylosing Spondylitis

Basit Öğe Kaydı
dc.contributor.authorÖnmez, Attlla
dc.contributor.authorAltun, Gulsah
dc.contributor.authorAkbaş, Türkay
dc.contributor.authorÖneç, Birgül
dc.date.accessioned2025-03-24T19:50:25Z
dc.date.available2025-03-24T19:50:25Z
dc.date.issued2022
dc.departmentDüzce Üniversitesi
dc.description.abstractTumor necrosis factor-alpha (TNF-?), which is produced by macrophages and activated T lymphocyte cells, plays a main role in inducing further stimulation of other inflammatory cells. Anti-TNF-? drugs are used for induction and preservation of remission in patients with Ankylosing spondylitis. Etanercept, which is one of the most used Anti-TNF-? drugs, has side effects such as cytopenia but isolated thrombocytopenia is an uncommon adverse event. We report the case of a 40-year-old man diagnosed with Ankylosing spondylitis who developed Etanercept-induced isolated thrombocytopenia.
dc.identifier.endpage29
dc.identifier.issn2791-9250
dc.identifier.issue1
dc.identifier.startpage28
dc.identifier.urihttps://hdl.handle.net/20.500.12684/19796
dc.identifier.volume2
dc.language.isoen
dc.publisherDAHUDER
dc.relation.ispartofDAHUDER Medical Journal
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_DergiPark_20250324
dc.subjectThrombocytopenia|Ankylosing Spondylitis|adverse effect|biological agents
dc.titleEtanercept-Induced Thrombocytopenia In A Patient With Ankylosing Spondylitis
dc.typeArticle

Dosyalar

Koleksiyon

Öksüz Yayınlar Koleksiyonu